Although Iterum Therapeutics PLC’s sulopenem missed the primary endpoint in the SURE 3 trial in complicated intra-abdominal infections, the four-year-old company believes the Phase III data could still be supportive of a new drug application if the firm’s other Phase III trials are positive.
The company hopes to file an NDA with the US Food and Drug Administration after two other trials, SURE 1...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
